{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:47:52Z","timestamp":1740138472646,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"crossref","award":["302622\/2015-2"],"award-info":[{"award-number":["302622\/2015-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"crossref","award":["BEX 14679\/13-2"],"award-info":[{"award-number":["BEX 14679\/13-2"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s12032-017-1067-2","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T03:50:50Z","timestamp":1512359450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intravesical Thalidomide boosts bacillus Calmette-Gu\u00e9rin (BCG) in non-muscle invasive bladder cancer treatment"],"prefix":"10.1007","volume":"35","author":[{"given":"Gabriela R.","family":"Passos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana A.","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio J. A.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amilcar C.","family":"de Mattos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-414X","authenticated-orcid":false,"given":"Leonardo O.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,4]]},"reference":[{"key":"1067_CR1","volume-title":"Cancer Facts & Figures\u00a02016","author":"American Cancer Society","year":"2016","unstructured":"American Cancer Society. Cancer Facts & Figures\u00a02016. Atlanta: American Cancer Society; 2016."},{"issue":"5","key":"1067_CR2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1464-410X.2010.09517.x","volume":"107","author":"SK Tickoo","year":"2011","unstructured":"Tickoo SK, Milowsky MI, Dhar N, Dudas ME, Gallagher DJ, Al-Ahmadie H, et al. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int. 2011;107(5):844\u20139.","journal-title":"BJU Int"},{"issue":"12","key":"1067_CR3","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0167-5699(99)01531-5","volume":"20","author":"JB Marriott","year":"1999","unstructured":"Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today. 1999;20(12):538\u201340.","journal-title":"Immunol Today"},{"key":"1067_CR4","unstructured":"ClinicalTrials.gov identifier: NCT01373294. \n                        https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01373294?sect=X487016#othr\n                        \n                    . Accessed 26 Sept 2016."},{"issue":"2","key":"1067_CR5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.juro.2011.10.022","volume":"187","author":"LO Reis","year":"2012","unstructured":"Reis LO, Ferreira U, Billis A, Cagnon VH, F\u00e1varo WJ. Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Gu\u00e9rin immunotherapy for nonmuscle invasive bladder cancer. J Urol. 2012;187(2):438\u201345.","journal-title":"J Urol"},{"issue":"2","key":"1067_CR6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.juro.2014.08.106","volume":"193","author":"KL Ferrari","year":"2015","unstructured":"Ferrari KL, de Camargo JA, Rocha GZ, Carvalheira JB, Saad MJ, Billis A, et al. Intravesical bacillus Calmette-Gu\u00e9rin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer. J Urol. 2015;193(2):682\u20139.","journal-title":"J Urol"},{"key":"1067_CR7","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/2326-6066.CIR-16-0267","volume":"5","author":"M Kates","year":"2017","unstructured":"Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, et al. Intravesical BCG induces CD4+ T-cell expansion in an immune competent model of bladder cancer. Cancer Immunol Res. 2017;5:594\u2013603.","journal-title":"Cancer Immunol Res"},{"issue":"Suppl 2","key":"1067_CR8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1590\/S0102-86502011000800019","volume":"26","author":"LO Reis","year":"2011","unstructured":"Reis LO, Sopena JM, F\u00e1varo WJ, Martin MC, Sim\u00e3o AF, Reis RB, et al. Anatomical features of the urethra and urinary bladder catheterization in female mice and rats. An essential translational tool. Acta Cir Bras. 2011;26(Suppl 2):106\u201310.","journal-title":"Acta Cir Bras"},{"issue":"1\u20132","key":"1067_CR9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jns.2015.02.043","volume":"351","author":"G Palencia","year":"2015","unstructured":"Palencia G, Medrano J, Ortiz-Plata A, Farf\u00e1n DJ, Sotelo J, S\u00e1nchez A, et al. Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral ischemia\/reperfusion injury in rats. J Neurol Sci. 2015;351(1\u20132):78\u201387.","journal-title":"J Neurol Sci"},{"issue":"2","key":"1067_CR10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/106689690501300203","volume":"13","author":"R Montironi","year":"2005","unstructured":"Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol. 2005;13(2):143\u201353.","journal-title":"Int J Surg Pathol"},{"issue":"11","key":"1067_CR11","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.3109\/10428194.2010.509893","volume":"51","author":"KD Boyd","year":"2010","unstructured":"Boyd KD, Walker BA, Wardell CP, Ross FM, Gregory WM, Davies FE, et al. High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma. 2010;51(11):2126\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"5982","key":"1067_CR12","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1126\/science.1187532","volume":"328","author":"RJ Dowling","year":"2010","unstructured":"Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010;328(5982):1172\u20136.","journal-title":"Science"},{"issue":"9","key":"1067_CR13","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1634\/theoncologist.2010-0118","volume":"15","author":"SJ Ong","year":"2010","unstructured":"Ong SJ, Teo M, Lim KH, Choo SP, Toh HC. Rapamycin and Thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report. Oncologist. 2010;15(9):965\u20138.","journal-title":"Oncologist"},{"issue":"9","key":"1067_CR14","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91(9):4082\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1067_CR15","first-page":"941","volume":"56","author":"DM Brizel","year":"1996","unstructured":"Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941\u20139437.","journal-title":"Cancer Res"},{"key":"1067_CR16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/359843a0","volume":"359","author":"D Schweiki","year":"1992","unstructured":"Schweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. Nature. 1992;359:843\u20135.","journal-title":"Nature"},{"issue":"2","key":"1067_CR17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2004.04.008","volume":"46","author":"VE Theodoropoulos","year":"2004","unstructured":"Theodoropoulos VE, Lazaris ACh, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, et al. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol. 2004;46(2):200\u20138.","journal-title":"Eur Urol"},{"issue":"2","key":"1067_CR18","first-page":"471","volume":"8","author":"T Onita","year":"2002","unstructured":"Onita T, Ji PG, Xuan JW, Sakai H, Kanetake H, Maxwell PH, et al. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1\/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res. 2002;8(2):471\u201380.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1067_CR19","first-page":"909","volume":"14","author":"V Palit","year":"2005","unstructured":"Palit V, Phillips RM, Puri R, Shah T, Bibby MC. Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol Rep. 2005;14(4):909\u201313.","journal-title":"Oncol Rep"},{"key":"1067_CR20","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019reilly","year":"2006","unstructured":"O\u2019reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500\u20138.","journal-title":"Cancer Res"},{"issue":"11","key":"1067_CR21","doi-asserted-by":"crossref","first-page":"e27509","DOI":"10.1371\/journal.pone.0027509","volume":"6","author":"R Nawroth","year":"2011","unstructured":"Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, Krause BJ, et al. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS ONE. 2011;6(11):e27509.","journal-title":"PLoS ONE"},{"issue":"12","key":"1067_CR22","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99(12):4525\u201330.","journal-title":"Blood"},{"issue":"3B","key":"1067_CR23","first-page":"2481","volume":"23","author":"X Li","year":"2003","unstructured":"Li X, Liu X, Wang J, Wang Z, Jiang W, Reed E, Zhang Y, Liu Y, Li QQ. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res. 2003;23(3B):2481\u20137.","journal-title":"Anticancer Res"},{"issue":"8","key":"1067_CR24","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.urolonc.2012.05.007","volume":"31","author":"GG Jinesh","year":"2013","unstructured":"Jinesh GG, Lee EK, Tran J, Kamat AM. Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo. Urol Oncol. 2013;31(8):1676\u201382.","journal-title":"Urol Oncol"},{"issue":"7","key":"1067_CR25","first-page":"3383","volume":"34","author":"W Jian","year":"2014","unstructured":"Jian W, Levitt JM, Lerner SP, Sonpavde G. The preclinical activity of Lenalidomide in indolent urothelial carcinoma. Anticancer Res. 2014;34(7):3383\u20139.","journal-title":"Anticancer Res"},{"issue":"5","key":"1067_CR26","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3892\/ijo.2015.3155","volume":"47","author":"YT Huang","year":"2015","unstructured":"Huang YT, Cheng CC, Chiu TH, Lai PC. Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer. Int J Oncol. 2015;47(5):1711\u201324.","journal-title":"Int J Oncol"},{"issue":"4","key":"1067_CR27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1054\/bjoc.1999.1004","volume":"82","author":"T Eisen","year":"2000","unstructured":"Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000;82(4):812\u20137.","journal-title":"Br J Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-017-1067-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T06:45:30Z","timestamp":1515048330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-017-1067-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1007\/s12032-017-1067-2","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2017,12,4]]},"article-number":"3"}}